A phase 2 asthma study of Upstream Bio’s TSLP receptor antagonist has hit its primary endpoint. But, with only the 12-week regimen achieving a Tezspire-like reduction in the annualized asthma ...

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the candidate actually performed. The U.K.-based Big ...